Antibodies Binding OX40L Combined with Hyaluronidase, Inflammatory Treatment
Summary
The USPTO published patent application US20260108603A1 on April 23, 2026, disclosing compositions and combinations comprising an antibody that binds OX40L and a hyaluronidase or variant thereof for treating inflammatory disorders or diseases in human patients. Inventors are Aaron NOYES and Rebecca Lucille DABORA, with an original filing date of October 17, 2025, and application number 19361800. This A1 publication makes the application publicly accessible for examination purposes.
“Described herein are compositions and combinations comprising an antibody that binds OX40L and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108603A1 covering compositions that combine an antibody targeting OX40L (a costimulatory molecule on activated T cells linked to inflammatory immune responses) with hyaluronidase or a variant thereof, along with methods of using these compositions to treat inflammatory disorders or diseases in human patients.
Pharmaceutical and biotechnology companies developing immunomodulatory therapies for inflammatory conditions should monitor this application as it represents a novel combination approach targeting the OX40L pathway. Patent applications do not themselves create compliance obligations but may inform freedom-to-operate analyses and competitive landscape assessments for parties active in inflammatory disease drug development.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODIES THAT BIND OX40L IN COMBINATION WITH HYALURONIDASE OR A VARIANT THEREOF
Application US20260108603A1 Kind: A1 Apr 23, 2026
Inventors
Aaron NOYES, Rebecca Lucille DABORA
Abstract
Described herein are compositions and combinations comprising an antibody that binds OX40L and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.
CPC Classifications
A61K 39/3955 A61K 38/47 C12Y 302/01035
Filing Date
2025-10-17
Application No.
19361800
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.